Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/119879
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Colom, Joan (Colom Farran) | - |
dc.contributor.author | Casas, Miquel | - |
dc.contributor.author | Pérez de los Cobos Peris, José C. | - |
dc.contributor.author | del Río, Miquel | - |
dc.contributor.author | Roncero, Carlos | - |
dc.contributor.author | Castells, Xavier | - |
dc.contributor.author | Valero, Sergi | - |
dc.contributor.author | Eiroá Orosa, Francisco José | - |
dc.contributor.author | Batlle, Francisca | - |
dc.contributor.author | Trujols i Albet, Joan | - |
dc.date.accessioned | 2018-02-15T17:03:53Z | - |
dc.date.available | 2018-02-15T17:03:53Z | - |
dc.date.issued | 2012-10 | - |
dc.identifier.issn | 1022-6877 | - |
dc.identifier.uri | http://hdl.handle.net/2445/119879 | - |
dc.description.abstract | The aim of this study was to evaluate the feasibility of conducting double-blind controlled randomized clinical trials using twice-a-day immediate-release oral diacetylmorphine (DAM) in heroin-dependent patients, by means of measuring the capacity of oral DAM to block opiate withdrawal and clinicians' ability to distinguish it from morphine and methadone. This was a randomized, phase II, double-blind, multicenter pilot study comparing immediate-release oral DAM, slow-release oral morphine and oral methadone administered twice a day during 10 days. Forty-five heroin-dependent patients were randomly assigned to these three treatment groups in an inpatient regime. Patients were stabilized with a mean of 350 mg (SD = 193) of immediate-release oral DAM, 108 mg (SD = 46.2) of slow-release oral morphine and 40 mg (SD = 17.9) of methadone. No statistically significant differences were found between any studied medication in clinical outcome. Neither patients nor clinicians were able to identify the administered medication. This study shows the feasibility of double-blind clinical trials using b.i.d. immediate-release oral DAM allowing further phase III clinical trials in the process of introducing oral DAM as a medication for heroin-dependent patients not responding to standard maintenance treatments. | - |
dc.format.extent | 18 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Karger | - |
dc.relation.isformatof | Versió postprint del document publicat a: https://doi.org/10.1159/000336849 | - |
dc.relation.ispartof | European Addiction Research, 2012, vol. 18, num. 6, p. 279-287 | - |
dc.relation.uri | https://doi.org/10.1159/000336849 | - |
dc.rights | (c) Karger, 2012 | - |
dc.source | Articles publicats en revistes (Psicologia Clínica i Psicobiologia) | - |
dc.subject.classification | Drogoaddicció | - |
dc.subject.classification | Opi | - |
dc.subject.classification | Desintoxicació de les drogues | - |
dc.subject.other | Drug addiction | - |
dc.subject.other | Opium | - |
dc.subject.other | Drug detoxification | - |
dc.title | Feasibility of Double-Blind Clinical Trials with Oral Diacetylmorphine: A Randomized Controlled Phase II Study in an Inpatient Setting | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.identifier.idgrec | 673542 | - |
dc.date.updated | 2018-02-15T17:03:53Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Psicologia Clínica i Psicobiologia) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
673542.pdf | 457.21 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.